Treatment of Prostate Cancer Using Anti-androgen Small Molecules


Castrate-resistant prostate cancer (CRPC) is characterized by androgen-independent cancer cells that have adapted to the depletion of hormones and continue to grow. Abnormal androgen receptor signaling is known to drive advanced castrate-resistant prostate cancer. The small molecule compounds of this invention are antiandrogens that target androgen receptor signaling in both androgen-independent and androgen-sensitive androgen receptor activity, and androgen receptors that are resistant to the current antiandrogens available.  Unlike the currently available antiandrogens, the new small molecules induce androgen receptor degradation and cell death in prostate cancer cells. Further, these compounds and methods can also induce degradation of other steroid hormone receptors demonstrating the possibility of treating a wider range of cancers.



Potential Commercial Applications: Competitive Advantages:
  • Series of steroid receptor compounds that cause cancer cell death
  • Method of using the compounds in cancer treatment
 
  • First small molecule antiandrogen treatment
  • Causes cell death, not just loss of function
  • Potential to treat other cancers through degradation of other steroid hormone receptors


Development Stage:
Discovery (Lead Identification)

Inventors:

Jane Trepel Neckers (NCI)  ➽ more inventions...

Yeong Kim (NCI)  ➽ more inventions...

Sunmin Lee (NCI)  ➽ more inventions...

Vineet Kumar (NCI)  ➽ more inventions...

Sanjay Malhotra (NCI)  ➽ more inventions...


Intellectual Property:
U.S. Application No. 61/497,129

Collaboration Opportunity:

Licensing only


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-015-2011
Updated: Nov 27, 2018